Tumor distribution and anti-tumor effect of doxorubicin following intrapulmonary administration to mice with metastatic lung tumor

被引:9
|
作者
Kanehira, Yukimune [1 ]
Togami, Kohei [1 ]
Tada, Hitoshi [1 ]
Chono, Sumio [1 ]
机构
[1] Hokkaido Pharmaceut Univ, Sch Pharm, Div Pharmaceut, 7-15-4-1 Maeda, Sapporo, Hokkaido 0068590, Japan
基金
日本学术振兴会;
关键词
Pulmonary drug delivery system; Lung cancer; B16F10; Anti-tumor agent; Tumor region distribution; EPITHELIAL LINING FLUID; ALVEOLAR MACROPHAGES; P-GLYCOPROTEIN; CANCER; CHEMOTHERAPY; CARCINOMA; CLARITHROMYCIN; RESISTANCE; MECHANISM; DELIVERY;
D O I
10.1016/j.jddst.2016.04.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present study evaluated the distribution of doxorubicin (DOX), as a fluorescent marker and an antitumor agent, to a lung tumor region following intrapulmonary administration. Using a Liquid Micro Sprayer (R), DOX (400 mu g/kg) was administered to mice with B16F10, which are murine melanoma cells that induce metastatic lung tumor. DOX concentrations in the lung following intrapulmonary administration were markedly higher than those following intravenous administration. On the other hand, DOX concentrations in serum following intrapulmonary administration were significantly lower than those following intravenous administration. DOX fluorescence after intrapulmonary administration was widely observed in the tumor region with P-glycoprotein expression. In contrast, DOX was not observed in the tumor region following intravenous administration. DOX administered intrapulmonarily suppressed the tumor growth than case of intravenous administration. These results indicate that intrapulmonary administration can efficiently deliver anti-tumor agents for lung cancer. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:143 / 148
页数:6
相关论文
共 50 条
  • [21] A comparative evaluation of anti-tumor activity following oral and intravenous delivery of doxorubicin in a xenograft model of breast tumor
    Rehan, Farah
    Karim, Md Emranul
    Ahemad, Nafees
    Shaikh, Mohd Farooq
    Gupta, Manish
    Gan, Siew Hua
    Chowdhury, Ezharul Hoque
    JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2022, 52 (06) : 787 - 804
  • [22] ANTI-TUMOR EFFECT OF CIMETIDINE
    ARMITAGE, JO
    SIDNER, RD
    LANCET, 1979, 1 (8121): : 882 - 883
  • [23] ANTI-TUMOR EFFECT OF TUFTSIN
    NISHIOKA, K
    BABCOCK, GE
    PHILLIPS, JH
    NOYES, RD
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 1981, 41 (DEC) : 13 - 18
  • [24] ANTI-TUMOR EFFECT OF RETINOIDS
    MAHRLE, G
    BERGER, H
    ZEITSCHRIFT FUR HAUTKRANKHEITEN H&G, 1982, 57 (06): : 429 - &
  • [25] The anti-tumor effect of silybin
    Guo, Zhenli
    Li, An
    Song, Musheng
    Zhang, Gai
    Zhong, Jinghua
    MINERVA MEDICA, 2023,
  • [26] ANTI-TUMOR DRUG TOXICITY IN TUMOR-FREE AND TUMOR-BEARING MICE
    HARRISON, SD
    GILES, HD
    DENINE, EP
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1980, 4 (03) : 199 - 204
  • [27] Administration of MIP-3α gene to the tumor following radiation therapy boosts anti-tumor immunity in a murine model of lung carcinoma
    Zhu, B
    Zou, L
    Cheng, XM
    Lin, ZH
    Duan, YZ
    Wu, YZ
    Zhou, F
    Chen, ZT
    IMMUNOLOGY LETTERS, 2006, 103 (02) : 101 - 107
  • [28] STRUCTURE AND ANTI-TUMOR EFFECT OF PSK(KRESTIN) - MECHANISTIC ASPECTS OF THE ANTI-TUMOR ACTIVITY
    MUTO, S
    KOBAYASHI, A
    OHARA, M
    MATSUNAGA, K
    IKUZAWA, M
    FURUSHO, T
    YOSHIKUMI, C
    HOTTA, T
    YANAGISAWA, M
    INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1982, 4 (04): : 308 - 308
  • [29] INTENSE ANTI-TUMOR POTENCY IN A NEW DOXORUBICIN DERIVATIVE
    ACTON, EM
    TONG, GL
    WOLGEMUTH, RL
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1983, 24 (MAR): : 252 - 252
  • [30] Enhanced efficacy of anti-tumor liposomal doxorubicin by hyperthermia
    Liu, Ping
    Xu, Lisa Xuemin
    Zhang, Aili
    2006 28TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOLS 1-15, 2006, : 5275 - +